Choice of dopaminergic therapy among early, mild Parkinson disease subjects in North America

John L. Goudreau, Adriana Pérez, Michael J. Aminoff, James T. Boyd, Keith D. Burau, Chadwick W. Christine, Maureen Leehey, John Christopher Morgan

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The choice of dopaminergic therapy in early Parkinson disease (PD) is an important clinical decision, yet factors influencing this decision have not been extensively studied. We sought to investigate the factors that may be associated with the choice of dopaminergic therapy at the NINDS Exploratory Trials in PD (NET-PD) Long-Term Study-1 (LS1). NET-PD LS1 was a clinical trial of creatine versus placebo in participants with early, mild PD on stable doses of dopaminergic therapy. Baseline data from 1616 out of the 1741 participants were evaluated using univariable and multivariable logistic or generalized logit regression analyses for available factors associated with the choice of dopaminergic therapy. The dopaminergic therapy choice was determined as: (i) therapy that subjects recalled taking 180 days before the study; (ii) therapy at baseline; and (iii) the longest duration of therapy reported by participants. Younger age, higher education level, longer length of time since PD diagnosis and use of an adjunctive, non-dopaminergic or monoamine oxidase inhibitor medication were associated with more frequent use of dopamine agonist compared to levodopa or combination therapy.

Original languageEnglish (US)
Pages (from-to)74-81
Number of pages8
JournalJournal of the Neurological Sciences
Volume366
DOIs
StatePublished - Jul 15 2016

Fingerprint

North America
Parkinson Disease
National Institute of Neurological Disorders and Stroke
Therapeutics
Monoamine Oxidase Inhibitors
Creatine
Dopamine Agonists
Levodopa
Placebos
Regression Analysis
Clinical Trials
Education

Keywords

  • Clinical trial
  • Dopamine agonists
  • Levodopa

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Choice of dopaminergic therapy among early, mild Parkinson disease subjects in North America. / Goudreau, John L.; Pérez, Adriana; Aminoff, Michael J.; Boyd, James T.; Burau, Keith D.; Christine, Chadwick W.; Leehey, Maureen; Morgan, John Christopher.

In: Journal of the Neurological Sciences, Vol. 366, 15.07.2016, p. 74-81.

Research output: Contribution to journalArticle

Goudreau, John L. ; Pérez, Adriana ; Aminoff, Michael J. ; Boyd, James T. ; Burau, Keith D. ; Christine, Chadwick W. ; Leehey, Maureen ; Morgan, John Christopher. / Choice of dopaminergic therapy among early, mild Parkinson disease subjects in North America. In: Journal of the Neurological Sciences. 2016 ; Vol. 366. pp. 74-81.
@article{990cfc615f32438dab10c038af7aafaa,
title = "Choice of dopaminergic therapy among early, mild Parkinson disease subjects in North America",
abstract = "The choice of dopaminergic therapy in early Parkinson disease (PD) is an important clinical decision, yet factors influencing this decision have not been extensively studied. We sought to investigate the factors that may be associated with the choice of dopaminergic therapy at the NINDS Exploratory Trials in PD (NET-PD) Long-Term Study-1 (LS1). NET-PD LS1 was a clinical trial of creatine versus placebo in participants with early, mild PD on stable doses of dopaminergic therapy. Baseline data from 1616 out of the 1741 participants were evaluated using univariable and multivariable logistic or generalized logit regression analyses for available factors associated with the choice of dopaminergic therapy. The dopaminergic therapy choice was determined as: (i) therapy that subjects recalled taking 180 days before the study; (ii) therapy at baseline; and (iii) the longest duration of therapy reported by participants. Younger age, higher education level, longer length of time since PD diagnosis and use of an adjunctive, non-dopaminergic or monoamine oxidase inhibitor medication were associated with more frequent use of dopamine agonist compared to levodopa or combination therapy.",
keywords = "Clinical trial, Dopamine agonists, Levodopa",
author = "Goudreau, {John L.} and Adriana P{\'e}rez and Aminoff, {Michael J.} and Boyd, {James T.} and Burau, {Keith D.} and Christine, {Chadwick W.} and Maureen Leehey and Morgan, {John Christopher}",
year = "2016",
month = "7",
day = "15",
doi = "10.1016/j.jns.2016.04.021",
language = "English (US)",
volume = "366",
pages = "74--81",
journal = "Journal of the Neurological Sciences",
issn = "0022-510X",
publisher = "Elsevier",

}

TY - JOUR

T1 - Choice of dopaminergic therapy among early, mild Parkinson disease subjects in North America

AU - Goudreau, John L.

AU - Pérez, Adriana

AU - Aminoff, Michael J.

AU - Boyd, James T.

AU - Burau, Keith D.

AU - Christine, Chadwick W.

AU - Leehey, Maureen

AU - Morgan, John Christopher

PY - 2016/7/15

Y1 - 2016/7/15

N2 - The choice of dopaminergic therapy in early Parkinson disease (PD) is an important clinical decision, yet factors influencing this decision have not been extensively studied. We sought to investigate the factors that may be associated with the choice of dopaminergic therapy at the NINDS Exploratory Trials in PD (NET-PD) Long-Term Study-1 (LS1). NET-PD LS1 was a clinical trial of creatine versus placebo in participants with early, mild PD on stable doses of dopaminergic therapy. Baseline data from 1616 out of the 1741 participants were evaluated using univariable and multivariable logistic or generalized logit regression analyses for available factors associated with the choice of dopaminergic therapy. The dopaminergic therapy choice was determined as: (i) therapy that subjects recalled taking 180 days before the study; (ii) therapy at baseline; and (iii) the longest duration of therapy reported by participants. Younger age, higher education level, longer length of time since PD diagnosis and use of an adjunctive, non-dopaminergic or monoamine oxidase inhibitor medication were associated with more frequent use of dopamine agonist compared to levodopa or combination therapy.

AB - The choice of dopaminergic therapy in early Parkinson disease (PD) is an important clinical decision, yet factors influencing this decision have not been extensively studied. We sought to investigate the factors that may be associated with the choice of dopaminergic therapy at the NINDS Exploratory Trials in PD (NET-PD) Long-Term Study-1 (LS1). NET-PD LS1 was a clinical trial of creatine versus placebo in participants with early, mild PD on stable doses of dopaminergic therapy. Baseline data from 1616 out of the 1741 participants were evaluated using univariable and multivariable logistic or generalized logit regression analyses for available factors associated with the choice of dopaminergic therapy. The dopaminergic therapy choice was determined as: (i) therapy that subjects recalled taking 180 days before the study; (ii) therapy at baseline; and (iii) the longest duration of therapy reported by participants. Younger age, higher education level, longer length of time since PD diagnosis and use of an adjunctive, non-dopaminergic or monoamine oxidase inhibitor medication were associated with more frequent use of dopamine agonist compared to levodopa or combination therapy.

KW - Clinical trial

KW - Dopamine agonists

KW - Levodopa

UR - http://www.scopus.com/inward/record.url?scp=84968538122&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84968538122&partnerID=8YFLogxK

U2 - 10.1016/j.jns.2016.04.021

DO - 10.1016/j.jns.2016.04.021

M3 - Article

C2 - 27288780

AN - SCOPUS:84968538122

VL - 366

SP - 74

EP - 81

JO - Journal of the Neurological Sciences

JF - Journal of the Neurological Sciences

SN - 0022-510X

ER -